BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18355919)

  • 21. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
    Ullmann AJ; Hess G; Kolbe K; Friedrich-Freksa A; Meyer RG; Gschaidmeier H; Huber C; Fischer T
    Keio J Med; 2003 Sep; 52(3):182-8. PubMed ID: 14529151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias.
    Gupta V; Kamel-Reid S; Minden MD; Lipton JH; Brandwein J; Messner HA
    Hematology; 2003 Jun; 8(3):139-43. PubMed ID: 12745646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice.
    Yanada M; Naoe T
    Leuk Lymphoma; 2006 Sep; 47(9):1747-53. PubMed ID: 17064984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
    Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
    Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
    de Labarthe A; Rousselot P; Huguet-Rigal F; Delabesse E; Witz F; Maury S; Réa D; Cayuela JM; Vekemans MC; Reman O; Buzyn A; Pigneux A; Escoffre M; Chalandon Y; MacIntyre E; Lhéritier V; Vernant JP; Thomas X; Ifrah N; Dombret H;
    Blood; 2007 Feb; 109(4):1408-13. PubMed ID: 17062730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy.
    Ohno R;
    Curr Hematol Malig Rep; 2006 Sep; 1(3):180-7. PubMed ID: 20425349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
    Hernández-Boluda JC; Cervantes F
    Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ohno R
    Curr Oncol Rep; 2008 Sep; 10(5):379-87. PubMed ID: 18706265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
    Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ
    Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Kovitz C; Kantarjian H; Garcia-Manero G; Abruzzo LV; Cortes J
    Blood; 2006 Oct; 108(8):2811-3. PubMed ID: 16809614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
    Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Wassmann B; Pfeifer H; Stadler M; Bornhaüser M; Bug G; Scheuring UJ; Brück P; Stelljes M; Schwerdtfeger R; Basara N; Perz J; Bunjes D; Ledderose G; Mahlberg R; Binckebanck A; Gschaidmeier H; Hoelzer D; Ottmann OG
    Blood; 2005 Jul; 106(2):458-63. PubMed ID: 15817679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
    Kantarjian HM; O'Brien S; Cortes JE; Smith TL; Rios MB; Shan J; Yang Y; Giles FJ; Thomas DA; Faderl S; Garcia-Manero G; Jeha S; Wierda W; Issa JP; Kornblau SM; Keating M; Resta D; Capdeville R; Talpaz M
    Clin Cancer Res; 2002 Jul; 8(7):2167-76. PubMed ID: 12114417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
    Ottmann OG; Hoelzer D
    Hematol J; 2002; 3(1):2-6. PubMed ID: 11960387
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.